• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    11/14/24 7:07:26 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCYX alert in real time by email
    SC 13G/A 1 d11530478_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

     

    Scynexis, Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

     

    811292200
    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No. 811292200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Partners Management LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,040,810  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,040,810  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,040,810  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%1  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     

    1 The percentage of ownership based on 37,856,463 shares of Common Stock of the Company outstanding as of August 1, 2024, as reported on the Issuer’s Form 10-Q filed on August 8, 2024.

     
     

     

     

    CUSIP No. 811292200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Partners Management (GP) LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,040,810  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,040,810  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,040,810  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%2  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    2 The percentage of ownership based on 37,856,463 shares of Common Stock of the Company outstanding as of August 1, 2024, as reported on the Issuer’s Form 10-Q filed on August 8, 2024.

     
     

     

     

    CUSIP No. 811292200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Capital Partners Fund (GP) LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,040,810  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,040,810  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,040,810  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%3  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, PN

     

    3 The percentage of ownership based on 37,856,463 shares of Common Stock of the Company outstanding as of August 1, 2024, as reported on the Issuer’s Form 10-Q filed on August 8, 2024.

     
     

     

     

    CUSIP No. 811292200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Capital Partners (GP) LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,040,810  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,040,810  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,040,810  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%4  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    4 The percentage of ownership based on 37,856,463 shares of Common Stock of the Company outstanding as of August 1, 2024, as reported on the Issuer’s Form 10-Q filed on August 8, 2024.

     
     

     

     

    CUSIP No. 811292200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Master Fund LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,177,203  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,177,203  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,177,203  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%5  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, PN

     

    5 The percentage of ownership based on 37,856,463 shares of Common Stock of the Company outstanding as of August 1, 2024, as reported on the Issuer’s Form 10-Q filed on August 8, 2024.

     
     

     

     

    CUSIP No. 811292200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Private Master Fund I LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,065,207  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,065,207  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,065,207  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%6  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, PN

     

     


    6 The percentage of ownership based on 37,856,463 shares of Common Stock of the Company outstanding as of August 1, 2024, as reported on the Issuer’s Form 10-Q filed on August 8, 2024.

     
     

     

    CUSIP No. 811292200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      David Witzke  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,040,810  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,040,810  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,040,810  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%7  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     


    7 The percentage of ownership based on 37,856,463 shares of Common Stock of the Company outstanding as of August 1, 2024, as reported on the Issuer’s Form 10-Q filed on August 8, 2024.

     
     

     

    CUSIP No. 811292200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Michael Gregory  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,040,810  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,040,810  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,040,810  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%8  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     


    8 The percentage of ownership based on 37,856,463 shares of Common Stock of the Company outstanding as of August 1, 2024, as reported on the Issuer’s Form 10-Q filed on August 8, 2024.

     
     

     

     

    Item 1. (a). Name of Issuer:  
           
        Scynexis, Inc.  

     

      (b). Address of issuer's principal executive offices:  
           
       

    1 Evertrust Plaza, 13th Floor

    Jersey City, New Jersey 07302

    United States of America

     

     

    Item 2. (a). Name of person filing:  
           
       

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

    Avidity Private Master Fund I LP

    David Witzke

    Michael Gregory

     

     

      (b). Address or principal business office or, if none, residence:  
           
       

    Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Partners Management (GP) LLC

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Capital Partners Fund (GP) LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Capital Partners (GP) LLC

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Master Fund LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Private Master Fund I LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

     

     
     

     

     

     

    David Witzke

    c/o Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Michael Gregory

    c/o Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

     

      (c). Citizenship:  
           
       

    Avidity Partners Management LP– Delaware

    Avidity Partners Management (GP) LLC – Delaware

    Avidity Capital Partners Fund (GP) LP – Delaware

    Avidity Capital Partners (GP) LLC – Delaware

    Avidity Master Fund LP – Cayman Islands

    Avidity Private Master Fund I LP – Cayman Islands

    David Witzke – United States of America

    Michael Gregory – United States of America

     

     

      (d).   Title of class of securities:  
           
       

    Common Stock, par value $0.001 per share

     

     

     

      (e). CUSIP No.:  
           
        811292200  

     

    Item 3.   If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

      (b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

      (c) [_] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

      (d) [_] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) [_] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j)   [_] A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

      (k)   [_] Group, in accordance with §240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     
     

     

     

     
    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:
         
       

    Avidity Partners Management LP: 4,040,810

    Avidity Partners Management (GP) LLC: 4,040,810

    Avidity Capital Partners Fund (GP) LP: 4,040,810

    Avidity Capital Partners (GP) LLC: 4,040,810

    Avidity Master Fund LP: 4,177,203

    Avidity Private Master Fund I LP: 4,065,207

    David Witzke: 4,040,810

    Michael Gregory: 4,040,810

     

      (b) Percent of class:
         
       

    Avidity Partners Management LP: 9.9%

    Avidity Partners Management (GP) LLC: 9.9%

    Avidity Capital Partners Fund (GP) LP: 9.9%

    Avidity Capital Partners (GP) LLC: 9.9%

    Avidity Master Fund LP: 9.9%

    Avidity Private Master Fund I LP: 9.9%

    David Witzke: 9.9%

    Michael Gregory: 9.9%

     

      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote

    Avidity Partners Management LP: 0

    Avidity Partners Management (GP) LLC: 0

    Avidity Capital Partners Fund (GP) LP: 0

    Avidity Capital Partners (GP) LLC: 0

    Avidity Master Fund LP: 0

    Avidity Private Master Fund I LP: 0

    David Witzke: 0

    Michael Gregory: 0

     

    ,

             
        (ii)   Shared power to vote or to direct the vote

    Avidity Partners Management LP: 4,040,810

    Avidity Partners Management (GP) LLC: 4,040,810

    Avidity Capital Partners Fund (GP) LP: 4,040,810

    Avidity Capital Partners (GP) LLC: 4,040,810

    Avidity Master Fund LP: 4,177,203

    Avidity Private Master Fund I LP: 4,065,207

    David Witzke: 4,040,810

    Michael Gregory: 4,040,810

     
             
        (iii) Sole power to dispose or to direct the disposition of

    Avidity Partners Management LP: 0

    Avidity Partners Management (GP) LLC: 0

    Avidity Capital Partners Fund (GP) LP: 0

    Avidity Capital Partners (GP) LLC: 0

    Avidity Master Fund LP: 0

    Avidity Private Master Fund I LP: 0

    David Witzke: 0

    Michael Gregory: 0

     

    ,

             
        (iv)   Shared power to dispose or to direct the disposition of

    Avidity Partners Management LP: 4,040,810

    Avidity Partners Management (GP) LLC: 4,040,810

    Avidity Capital Partners Fund (GP) LP: 4,040,810

    Avidity Capital Partners (GP) LLC: 4,040,810

    Avidity Master Fund LP: 4,177,203

    Avidity Private Master Fund I LP: 4,065,207

    David Witzke: 4,040,810

    Michael Gregory: 4,040,810

     

    .

             

     

     
     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [__].
     
      N/A
       

     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

      N/A
       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

     

    If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

      N/A
       

     

    Item 8. Identification and Classification of Members of the Group.

     

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

     

      N/A
       
    Item 9. Notice of Dissolution of Group.

     

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

      N/A
       

     

    Item 10. Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

     

     

    November 14, 2024

      (Date)
       
     

    David Witzke

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

    Avidity Private Master Fund I LP

     

      By: /s/ David Witzke
      David Witzke, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP and Avidity Private Master Fund I LP))
       
     

    Michael Gregory

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

    Avidity Private Master Fund I LP

     

      By: /s/Michael Gregory
      Michael Gregory, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP and Avidity Private Master Fund I LP))

     

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

     

     

    Exhibit 1

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Scynexis, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing

     The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

     

    IN WITNESS WHEREOF, the undersigned hereby execute this Agreement as of November 14, 2024.

           
     

    David Witzke

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

    Avidity Private Master Fund I LP

     

    /s/ David Witzke

     
      David Witzke, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP and Avidity Private Master Fund I LP))
         
      Michael Gregory
      Avidity Partners Management LP
      Avidity Partners Management (GP) LLC
      Avidity Capital Partners Fund (GP) LP
     

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

    Avidity Private Master Fund I LP

         
      By:  /s/ Michael Gregory  
      Michael Gregory, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP and Avidity Private Master Fund I LP))

    Get the next $SCYX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCYX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCYX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

      JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria being held from April 11-15, 2025. SCY-247 is being developed to address systemic fungal diseases, with a key focus on invasive fungal infections where resistance to current limited treatment options is a significant concern. These presentations at ESCMID Global

      4/8/25 8:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

      The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) congress, April 11-15, 2025 in Vienna, Austria.SCYNEXIS continues to make progress towards the restart of the Phase 3 MARIO study in invasive candidiasis. The Company anticipates the restart, pending the FDA's lifting of the clinical hold, in the second quarter of 2025.SCYNEXIS ended 2024 with cash, cash equivalents and investments of $75.1 million, and projects a cash runway into Q3 2026. JERSEY CITY, N.J

      3/12/25 5:08:56 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

      JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the dosing of the first cohort of subjects in its Phase 1 trial of SCY-247, the Company's second-generation triterpenoid antifungal in development for the treatment of severe invasive fungal infections.   "We are pleased to advance our potent, second-generation fungerp candidate SCY-247 into the clinic in a Phase 1 study," said David Angulo, M.D., President and Chief Executive Officer. "SCY-247 has consistently shown promising results in prec

      12/18/24 8:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

      Submission status for SCYNEXIS, INC's drug BREXAFEMME (ORIG-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

      6/2/21 11:20:46 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

      Submission status for SCYNEXIS, INC's drug BREXAFEMME (SUPPL-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

      6/2/21 9:57:42 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Angulo Gonzalez David was granted 23,000 shares, increasing direct ownership by 3% to 816,598 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      4/10/25 8:02:09 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Angulo Gonzalez David was granted 18,800 shares, increasing direct ownership by 2% to 793,598 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      3/20/25 7:39:22 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Sukenick Scott was granted 92,511 shares, increasing direct ownership by 27% to 436,706 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      1/27/25 4:05:22 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by SCYNEXIS Inc.

      DEFA14A - SCYNEXIS INC (0001178253) (Filer)

      4/30/25 4:03:33 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by SCYNEXIS Inc.

      DEF 14A - SCYNEXIS INC (0001178253) (Filer)

      4/30/25 4:01:58 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by SCYNEXIS Inc.

      10-K - SCYNEXIS INC (0001178253) (Filer)

      3/12/25 4:55:31 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      9/16/24 8:00:27 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Leadership Updates

    Live Leadership Updates

    See more

    $SCYX
    Financials

    Live finance-specific insights

    See more
    • AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

      Lyon - France, July 24, 2023 (GLOBE NEWSWIRE) -- AUROBAC THERAPEUTICS WELCOMES TWO NEW INDEPENDENT MEMBERS TO ITS BOARD: MANOS PERROS, AS CHAIRMAN, AND MARCO TAGLIETTI Dr Manos Perros and Dr Marco Taglietti are appointed new Independent Members of the Board of AUROBAC THERAPEUTICSDr Perros becomes Chairman of the Board These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization Lyon (France), Thursday July 24, 2023 AUROBAC THERAPEUTICS SAS, a biopharmaceutical company developing the next generation of products to fight antimicrobial resistance (AMR), is delighted to announce th

      7/24/23 8:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

      Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon Valley Bank, and the monetization of the 2020 New Jersey NOLsAppointed Christine Coyne as Chief Commercial Officer to lead the launch of ibrexafungerp (Brexafemme®) for the treatment of vaginal yeast infections, following expected approval by June 1st Began dosing patients in a Phase 1 trial of the IV formulation of ibrexafungerpFurther strengthened balance sheet and projected cash runway into 2023 JERSEY CITY, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology c

      5/17/21 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch

      Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. Ms. Coyne will play a significant role in the anticipated U.S. launch and commercialization of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal p

      5/11/21 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

      Brexafemme complements GSK's industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royaltiesSCYNEXIS retains rights to all other assets derived from enfumafungin, with GSK having a right of first negotiation to these pre-clinical and discovery stage assetsSCYNEXIS to host an investor call and webcast at 8:30 a.m. EDT today LONDON and JERSEY CITY, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- GSK plc (NYSE:GSK) and SCYNEXIS, Inc. (NASDAQ:SCYX), today announced they have entered into an exclusive licence agreement for Brexafemme (i

      3/30/23 7:05:00 AM ET
      $GSK
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications.Ivor Macleod, a 30-year biopharma veteran, joined SCYNEXIS as Chief Financial Officer.Marco Taglietti, M.D., to retire as President and Chief Executive Officer of SCYNEXIS and step down from the Board of Directors on December 31, 2022. David Angulo, M.D., Chief Medical Officer of SCYNEXIS will become President and Chief Executive Officer and join the Board effective January 1, 2023.BREXAFEMME® (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3

      11/9/22 7:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9

      JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2022. Conference call and webcast details: Investors (domestic): (844) 826-3033Investors (international): (412) 317-5185Webcast:  LinkConference ID: 10172836 A live audio webcast can be accessed by visiting the Investor Relations section of the Company'

      11/1/22 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital reiterated coverage on SCYNEXIS with a new price target

      Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $35.00 from $40.00 previously

      6/7/21 9:58:05 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital reiterated coverage on SCYNEXIS with a new price target

      Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $40.00 from $45.00 previously

      4/12/21 12:54:40 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group reiterated coverage on SCYNEXIS with a new price target

      Maxim Group reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $22.00 from $17.00 previously

      2/17/21 2:23:39 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

      SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

      11/14/24 7:07:26 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

      SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

      11/6/24 8:56:32 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

      SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

      10/7/24 1:38:20 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care